Key facts
- Vincerx Pharma, Inc. has 16 insiders with reported activity on this page.
- No net insider buy/sell flow is currently reported for the last year.
- Recent transaction rows are not currently available.
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 21 May 2025.
$0
Shares: 0
Insiders: 0
$0
Shares: 0
Insiders: 0
$0
Shares: 0
Insiders: 0
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13D/G
|
— |
5%
|
274,908
|
$19,244 | -$294,015 | 31 Mar 2025 | |
| Prosight Management, LP |
13D/G
|
— |
5%
|
111,755
|
$7,823 | $0 | 31 Dec 2024 | |
| Rubric Capital Management LP |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,107,000
|
— | — | 20 Jan 2022 | |
| Andrew I. McDonald |
3/4/5
|
Director, 10%+ Owner |
—
class O/S missing
|
15,000
|
— | — | 26 May 2022 | |
| Christopher P. Lowe |
3/4/5
|
Director |
—
class O/S missing
|
40,000
|
$37,972 | — | 24 Aug 2022 | |
| Alexander A. Seelenberger |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
155,280
mixed-class rows
|
$28,745 | — | 12 Aug 2024 | |
| SAGE RHINO CAPITAL LLC |
13D/G
|
— |
—
class O/S missing
|
4,260
|
$426 | $0 | 29 Jan 2025 | |
| Ahmed Hamdy MD |
3/4/5
|
Chief Executive Officer, Director |
—
class O/S missing
|
200,000
|
— | — | 12 Aug 2024 | |
| Raquel E. Izumi |
3/4/5
|
President and Chief Operations Officer, Director |
—
class O/S missing
|
165,000
|
— | — | 12 Aug 2024 | |
| Tom C. Thomas |
3/4/5
|
General Counsel and Chief Legal Officer |
—
class O/S missing
|
125,000
|
— | — | 12 Aug 2024 | |
| Hermes de Jesus Garban |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
55,250
|
— | — | 14 Feb 2022 | |
| Kevin Haas |
3/4/5
|
Acting Chief Financial Officer |
—
class O/S missing
|
42,776
|
— | — | 20 Dec 2024 | |
| Sooin Hwang |
3/4/5
|
Chief Business Officer |
—
class O/S missing
|
34,000
|
— | — | 14 Feb 2022 | |
| Xiaoming Zhang |
3/4/5
|
Chief Technology Officer |
—
class O/S missing
|
34,000
|
— | — | 14 Feb 2022 | |
| Brian J. Druker |
3/4/5
|
Director |
—
class O/S missing
|
15,000
|
— | — | 23 May 2024 | |
| Francisco D. Salva |
3/4/5
|
Director |
—
class O/S missing
|
15,000
|
— | — | 23 May 2024 | |
| John H. Lee |
3/4/5
|
Director |
—
class O/S missing
|
15,000
|
— | — | 23 May 2024 | |
| Laura I. Bushnell |
3/4/5
|
Director |
—
class O/S missing
|
15,000
|
— | — | 23 May 2024 | |
| Ruth E. Stevens |
3/4/5
|
Director |
—
class O/S missing
|
15,000
|
— | — | 23 May 2024 |
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||